Subscribe
Sign in
Home
Archive
About
Why We Partnered with Nxera Pharma
Antiverse Newsletter November 2024
Nov 28, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
Why We Partnered with Nxera Pharma
Copy link
Facebook
Email
Notes
More
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
The Multi-Target Partnership And Licensing Agreement Combines the Companies' GPCR Expertise To Bring Transformative Therapies To Patients.
Nov 5, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
Nxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Copy link
Facebook
Email
Notes
More
October 2024
Data Constraints in Drug Discovery
Antiverse Newsletter October 2024
Oct 31, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
Data Constraints in Drug Discovery
Copy link
Facebook
Email
Notes
More
Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform
This Brings The Company's Total Financing To £7.2M ($10.1M). The Funding Will Progress Antibodies Targeting Several G-Protein Coupled Receptors and Ion…
Oct 15, 2024
•
AntiverseHQ
1
Share this post
Updates at Antiverse
Antiverse Raises £3.5M ($4.6M) to Advance Generative AI Antibody Design Platform
Copy link
Facebook
Email
Notes
More
August 2024
What You Should Know About Weight Loss Drugs (If You Work In Pharma or Biotech)
Antiverse Newsletter August 2024
Aug 29, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
What You Should Know About Weight Loss Drugs (If You Work In Pharma or Biotech)
Copy link
Facebook
Email
Notes
More
July 2024
How to Discover Biologics for Challenging Targets
Antiverse Newsletter July 2024
Jul 30, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
How to Discover Biologics for Challenging Targets
Copy link
Facebook
Email
Notes
More
June 2024
Why are pharmaceutical companies turning to artificial intelligence for drug discovery?
Our top 5 reasons, based on our own research and previous collaborations with pharmaceutical companies.
Jun 27, 2024
•
AntiverseHQ
Share this post
Updates at Antiverse
Why are pharmaceutical companies turning to artificial intelligence for drug discovery?
Copy link
Facebook
Email
Notes
More
October 2023
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Two antibodies showing high specificity for PD-1 are now progressing to preclinical development as checkpoint inhibitors in oncology.
Oct 16, 2023
•
AntiverseHQ
1
Share this post
Updates at Antiverse
Antiverse and GlobalBio, Inc. extend collaboration to advance antibody cancer therapeutics
Copy link
Facebook
Email
Notes
More
March 2023
Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform
Seven human G-protein coupled receptor antibodies were characterised, showing high affinity and blocking function. $3 million USD investments will…
Mar 1, 2023
•
AntiverseHQ
1
Share this post
Updates at Antiverse
Antiverse raises funding and demonstrates therapeutic antibody identification with AI-driven drug discovery platform
Copy link
Facebook
Email
Notes
More
Share
Copy link
Facebook
Email
Notes
More
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
